Oral manifestation associated with avelumab Research Letter
| Authors: | Chung, K.; Singh, A.; Huryn, J. M.; Estilo, C. L. |
| Title: | Oral manifestation associated with avelumab |
| Abstract: | Emerging immunotherapies are becoming more prominent in treating various cancers. However, side effects and toxicities can induce systemic and oral manifestations which can be debilitating and negatively affect a patient's quality of life. Avelumab is a relatively recent immunotherapy drug that is used in the treatment of both renal and metastatic urothelial carcinomas. However, oral manifestation, to the best of our knowledge, has not been reported in the literature in association. The purpose of this case report is to describe an oral manifestation associated with avelumab, and subsequent management to obtain resolution of symptoms. © 2024 The Authors |
| Keywords: | mucositis; oral adverse events; immune checkpoint inhibitors; avelumab |
| Journal Title: | Oral Oncology Reports |
| Volume: | 9 |
| ISSN: | 2772-9060 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2024-03-01 |
| Start Page: | 100148 |
| Language: | English |
| DOI: | 10.1016/j.oor.2023.100148 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Letter -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PDF -- MSK corresponding author is Cherry Estilo -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work